Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
32 participants
INTERVENTIONAL
2022-04-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Stress-exposure is problematic for people trying to recover from substance use disorders (SUDs) because it weakens inhibition of automatic behaviors and increases drug craving and likelihood of relapse. However, paths through which stress affects behavior are incompletely understood and current SUD treatments do not target effects of stress on drug use.
This project will explore whether repetitive transcranial magnetic stimulation (rTMS) might improve treatment outcomes for people with OUD entering methadone treatment. The investigators will examine the impact of rTMS treatment over one of two theoretically-driven neural targets on substance use and cognitive outcomes associated with treatment success (executive function and emotional arousal).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will administer excitatory (10Hz) dlPFC rTMS and inhibitory (1Hz) mPFC rTMS (through an electromagnetic coil placed against the scalp) coupled with tasks of executive function and emotional arousal during stress and neutral conditions (guided imagery task using personalized scripts) in adults with OUD early in methadone treatment. The investigators will examine and compare how strengthening dlPFC activity or reducing mPFC activity may reverse stress-induced executive and emotional dysfunction, respectively, and improve treatment outcomes in persons with OUD seeking to abstain from opioid use.
A mixed design study will be used to examine the effects of active rTMS vs. sham (within subject) over one of two locations: 10 Hz dlPFC rTMS (group 1) or 1 Hz mPFC rTMS (group 2) in subjects receiving methadone treatment for OUD. The general rTMS treatment protocol will be the same for both groups and will consist of 2 stimulation sessions per day, separated by \~30min, for 5 days (10 total stimulation sessions per treatment protocol). The sham protocol will be the same except the sham rTMS coil will be used. Participants will be randomly assigned to groups and complete the 2 conditions (active vs. sham rTMS) in random order. Immediately prior to and after each 5-day rTMS treatment protocol, participants will attend an assessment visit when they will complete multiple tasks during both stress (guided imagery stressor) and neutral conditions. These tasks are designed to measure executive function, emotional arousal, and drug-seeking behavior.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active 10 Hz dlPFC rTMS
10 Hz dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
rTMS
Repetitive transcranial magnetic stimulation
Sham dlPFC rTMS
inactive dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
rTMS
Repetitive transcranial magnetic stimulation
Active 1 Hz mPFC rTMS
1 Hz medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
rTMS
Repetitive transcranial magnetic stimulation
Sham mPFC
inactive medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
rTMS
Repetitive transcranial magnetic stimulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rTMS
Repetitive transcranial magnetic stimulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. In methadone or buprenorphine treatment
3. Age 21-70 yr;
4. Right handed;
5. Males and non-pregnant/non-lactating females;
6. Cognitively intact (total IQ score \>80);
7. Use alcohol and/or marijuana \<4 times per week; each "time" should consist of \<2 marijuana "joint" equivalent and \<4 alcoholic drinks.
Exclusion Criteria
2. Current, regular (\>2 times/week) use of illicit drugs other than opioids (except cannabis);
3. Any past 24 hour use of drugs other than opioids or nicotine;
4. Urinalysis positive for pregnancy;
5. Medical conditions prohibiting use of rTMS;
6. Lifetime psychotic, bipolar, or potentially antisocial personality disorder;
7. Untreated or uncontrolled past-year diagnosis of major depression, generalized anxiety disorder, obsessive compulsive disorder, or post traumatic stress disorder;
8. Past-month SUD other than OUD or tobacco use disorder;
9. Acute/unstable illness making it unsafe for participation;
10. Any prohibited medications including: medications that lower seizure threshold, certain psychiatric medications, or prescription pain medications;
11. Chronic head or neck pain;
12. Past-month participation in a research study.
21 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wayne State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mark Greenwald, PhD
Professor of Psychiatry and Behavioral Neurosciences; and Director, Substance Abuse Research Division
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark K Greenwald, PhD
Role: STUDY_DIRECTOR
Wayne State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tolan Park Medical Building
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-21-01-3111
Identifier Type: -
Identifier Source: org_study_id